Furthermore, the rate of CD8+ T cells was positively related to longer progression-free survival (PFS) and OS in patients with PD-L1-positive NSCLC treated with immune checkpoint inhibitors (ICIs) (63). Here, CD8A is linked to non-small cell lung carcinoma.